Vikas Lifecare Limited – Board Update (21 Apr 2026)
Key Highlights
- Unaudited Results Approved: Standalone and consolidated financials for Q3 and H1 2025 were approved and limited‑reviewed by statutory auditors.
- Restatement Impact: Inclusion of a 51% stake in Ebix International Holdings Ltd (UK) (acquired via settlement) restated the half‑year profit to Rs 12,764.23 Lakh (previously a loss).
- Revenue Growth: Total income rose to Rs 14,165.94 Lakh for Q3, driven primarily by the Agro segment (≈ Rs 12,607 Lakh).
- Cash Position: Operating cash flow positive at Rs 40,109.79 Lakh; net cash increased to Rs 613.64 Lakh.
- Balance Sheet Strength: Assets Rs 80,523.63 Lakh, equity Rs 66,902.96 Lakh, liabilities Rs 13,620.69 Lakh.
Financial Metrics (Quarter ended 30‑Sep‑2025)
| Metric | Value (₹ Lakh) |
|---|---|
| Revenue from Operations | 14,097.78 |
| Other Income | 68.17 |
| Total Income | 14,165.94 |
| Net Profit/(Loss) (after restatement) | 12,764.23 |
| EPS (Basic/Diluted) | 0.69 |
| Cash & Cash Equivalents (EoQ) | 613.64 |
| Total Equity | 66,902.96 |
| Total Liabilities | 13,620.69 |
Strategic & Regulatory Developments
- Shareholder Consent via Postal Ballot Addendum – Board seeks approval for a range of ordinary‑course transactions (related‑party deals, loans, guarantees, charges). This could unlock additional financing or strategic investments.
- Related‑Party Transactions – Material related‑party deals disclosed for H1 2025; shareholder approval is still pending, posing a compliance risk.
- IGL Genesis Technologies Deal – Share purchase agreement signed; completion awaits approvals from Indraprastha Gas Ltd and IGTL. Until then, the transaction is not reflected in the books.
- Tax Evaluation of Ebix Settlement – The tax impact of receiving 51% of Ebix UK shares is under review; no tax charge has been recognized yet.
Risks & Opportunities
- Execution Risk: Delays in obtaining shareholder or regulatory approvals for related‑party and IGL Genesis transactions could affect liquidity and leverage.
- Tax Uncertainty: Potential tax liabilities from the Ebix UK acquisition could erode the reported profit.
- Customer Concentration: A few large customers account for a significant share of Agro segment revenue, exposing the firm to demand‑side volatility.
- Growth Potential: Strong revenue momentum in Agro and a sizable investment portfolio (₹ 42,841 Lakh in securities) provide upside if market conditions improve.
Outlook
- Score: 6 / 10 (moderately positive) – Profitability has improved markedly after restatement, and the balance sheet remains robust. However, pending approvals and tax uncertainties introduce material downside risk.
Prepared for investors on 21 April 2026 based on the Board’s announcement and unaudited financial statements.